Hao Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hao Ding has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hao Xu
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2 shared publications - Liuzhi Zhou
Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Qianhui Xu
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2 shared publications - Sitong Zhang
Second Affiliated Hospital of Zhejiang University 5 Hangzhou
2 shared publications - Weilin Wang
Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
2 shared publications - Xin Han
Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
2 shared publications
Latest Publications
- Open Access
- 1 September 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 948727
The value of immunotherapy in children with initial short-term frequent seizures
This study aimed to discuss clinical characteristics, therapy, and antibody prevalence in epilepsy (APE) score for short-term, frequent epileptic seizures in children who are autoimmune-antibody negative and respond well to immunotherapy. The clinical characteristics, imaging manifestations, electrophysiology, and effective treatment plan of 9 children who met the above criteria were retrospectively analyzed in the Pediatric Neurology Department of Qilu Hospital at Shandong University from June 2019 to December 2021. All 9 patients (6 boys, 3 girls; aged 13 months−11 years and 5 months, median 3.5 years) had acute-onset seizures within 3 months. All had previous normal growth/development with no family history of disease. Seizure types were focal motor seizures (6), generalized tonic-clonic seizures (2), and generalized secondary-to-focal (1); occurred >10 times/day; and lasted <1 min/episode. Formal treatment with ≥2 types of antiseizure medicine (ASM) achieved an unsatisfactory effect. Cranial magnetic resonance imaging showed an abnormal result in 1 case. The APE score was ≥4 in 3 cases and <4 in 6 cases. All patients experienced symptomatic relief with immunotherapy; subsequently, 8 patients were free of recurrence and 1 had significantly reduced seizure frequency. Autoimmune antibody screening is recommended for children who were previously well and have acute-onset epilepsy; high frequency, short-duration seizures; no good response to 2 types of ASM; and other etiologic factors excluded, even with APE score <4. Even with negative autoimmune antibody results, the possibility of autoimmune epilepsy should be considered for urgent initiation of immunotherapy, which can achieve good results.
- 1 September 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 948727
Open AccessThe value of immunotherapy in children with initial short-term frequent seizures
This study aimed to discuss clinical characteristics, therapy, and antibody prevalence in epilepsy (APE) score for short-term, frequent epileptic seizures in children who are autoimmune-antibody negative and respond well to immunotherapy. The clinical characteristics, imaging manifestations, electrophysiology, and effective treatment plan of 9 children who met the above criteria were retrospectively analyzed in the Pediatric Neurology Department of Qilu Hospital at Shandong University from June 2019 to December 2021. All 9 patients (6 boys, 3 girls; aged 13 months−11 years and 5 months, median 3.5 years) had acute-onset seizures within 3 months. All had previous normal growth/development with no family history of disease. Seizure types were focal motor seizures (6), generalized tonic-clonic seizures (2), and generalized secondary-to-focal (1); occurred >10 times/day; and lasted <1 min/episode. Formal treatment with ≥2 types of antiseizure medicine (ASM) achieved an unsatisfactory effect. Cranial magnetic resonance imaging showed an abnormal result in 1 case. The APE score was ≥4 in 3 cases and <4 in 6 cases. All patients experienced symptomatic relief with immunotherapy; subsequently, 8 patients were free of recurrence and 1 had significantly reduced seizure frequency. Autoimmune antibody screening is recommended for children who were previously well and have acute-onset epilepsy; high frequency, short-duration seizures; no good response to 2 types of ASM; and other etiologic factors excluded, even with APE score <4. Even with negative autoimmune antibody results, the possibility of autoimmune epilepsy should be considered for urgent initiation of immunotherapy, which can achieve good results.
- Open Access
- 27 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (1) , 104-111
Identification of Expression Pattern and Clinical Significance of the Small Cajal Body-specific RNA SCARNA16 in Hepatocellular Carcinoma
For high morbidity and mortality, hepatocellular carcinoma (HCC) becomes a major health issue worldwide. Nowadays, numerous non-coding RNAs (ncRNAs) are known to regulate the occurrence and pathogenesis of tumors. Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets. However, the potential function of the small Cajal body-specific RNA (scaRNA) SCARNA16, a newly identified ncRNA, remains to be explored in HCC.
- 27 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (1) , 104-111
Open AccessIdentification of Expression Pattern and Clinical Significance of the Small Cajal Body-specific RNA SCARNA16 in Hepatocellular Carcinoma
For high morbidity and mortality, hepatocellular carcinoma (HCC) becomes a major health issue worldwide. Nowadays, numerous non-coding RNAs (ncRNAs) are known to regulate the occurrence and pathogenesis of tumors. Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets. However, the potential function of the small Cajal body-specific RNA (scaRNA) SCARNA16, a newly identified ncRNA, remains to be explored in HCC.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 1-7
Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common and aggressive tumors in the world while the accuracy of the present tests for detecting HCC is poor. A novel diagnostic and prognostic biomarker for HCC is urgently needed. Overwhelming evidence has demonstrated the regulatory roles of small nucleolar RNA (snoRNA) in carcinogenesis. This study is aimed at analyzing the expression of a snoRNA, SNORA52, in HCC and exploring the correlation between its expression and various clinical characteristics of HCC patients. By using quantitative real‐time PCR, we found that SNORA52 was downregulated in HCC cell lines (P < 0.05) and HCC tissues (P < 0.001). Correlation analysis showed that the expression of SNORA52 was obviously associated with tumor size (P = 0.011), lesion number (P = 0.007), capsular invasion (P = 0.011), tumor differentiation degree (P = 0.046), and TNM stage (P = 0.004). The disease‐free survival (DFS) and overall survival (OS) analysis showed that patients with lower SNORA52 expression had a worse prognosis (P < 0.001). Univariate and multivariate Cox regression analysis showed that SNORA52 expression was a completely independent prognostic factor to predict DFS (P = 0.009) and OS (P = 0.012) of HCC patients. Overall, our findings showed SNORA52 expression levels were downregulated in HCC tissues and correlated with multiple clinical variables, and SNORA52 was an independent prognostic factor for HCC patients, which suggested that SNORA52 could function as a potential diagnostic and prognostic biomarker for HCC patients.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 1-7
Open AccessDownregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common and aggressive tumors in the world while the accuracy of the present tests for detecting HCC is poor. A novel diagnostic and prognostic biomarker for HCC is urgently needed. Overwhelming evidence has demonstrated the regulatory roles of small nucleolar RNA (snoRNA) in carcinogenesis. This study is aimed at analyzing the expression of a snoRNA, SNORA52, in HCC and exploring the correlation between its expression and various clinical characteristics of HCC patients. By using quantitative real‐time PCR, we found that SNORA52 was downregulated in HCC cell lines (P < 0.05) and HCC tissues (P < 0.001). Correlation analysis showed that the expression of SNORA52 was obviously associated with tumor size (P = 0.011), lesion number (P = 0.007), capsular invasion (P = 0.011), tumor differentiation degree (P = 0.046), and TNM stage (P = 0.004). The disease‐free survival (DFS) and overall survival (OS) analysis showed that patients with lower SNORA52 expression had a worse prognosis (P < 0.001). Univariate and multivariate Cox regression analysis showed that SNORA52 expression was a completely independent prognostic factor to predict DFS (P = 0.009) and OS (P = 0.012) of HCC patients. Overall, our findings showed SNORA52 expression levels were downregulated in HCC tissues and correlated with multiple clinical variables, and SNORA52 was an independent prognostic factor for HCC patients, which suggested that SNORA52 could function as a potential diagnostic and prognostic biomarker for HCC patients.